LONDON, Oct. 17, 2018 /PRNewswire/ -- Smith & Nephew
(LSE: SN, NYSE: SNN), the global medical technology business, today
announced at the Orthopaedic Trauma Association Annual Meeting in
Orlando, FL USA two new studies
showing positive clinical results and cost savings through using
its INTERTAN Intertrochanteric Antegrade Nail.
Patients recovering from a hip fracture often deal with various
complications, including decline in mobility and daily living
activities, and reduced ability to walk following fracture union.
More than 6% will require reoperation due to complications and
approximately 1 in 4 patients over the age of 65 die within 12
months of fracture.1,2,3
In a meta-analysis published in Rheumatology and Orthopedic
Medicine, the INTERTAN implant, which uses the Smith &
Nephew proprietary "Integrated Compression Screw", was compared to
other intertrochanteric nails using a customary "single screw". The
results showed that INTERTAN significantly reduced the risk of
implant related failures by 81% (p<0.00001) and revision surgery
by 65% (p<0.0001) when compared to single screw
nails.4
According to a further study, published in Journal of
Orthopaedic Surgery and Research, the improved clinical
outcomes from the meta-analysis also led to a cost savings of
$2700 USD per patient when using the
INTERTAN nail compared to single screw nails.5
"Hip fractures and their sequelae in elderly patients can
be debilitating, and potentially life threatening, and contribute a
significant portion to overall health care expenditure. These new
studies demonstrate that the Integrated Compression Screw used in
the INTERTAN nail not only improved the clinical outcomes for these
patients studied, but also reduced the cost to the overall
health economic system by reducing the revision rates, compared to
those that have been demonstrated in prior studies," commented J. Tracy Watson MD, Orthopaedic
Traumatologist, Phoenix,
Arizona and co-author for both papers.
"Smith & Nephew is dedicated to developing products that
will improve patient lives. The INTERTAN nail is a prime example of
the type of game-changing technology we at Smith & Nephew
strive to create. These two publications show how true innovation
can both make clinical improvement and provide economic benefits,"
said Andy Weymann MD, Chief Medical
Officer, Smith & Nephew.
For more information on the INTERTAN nail, please visit us at
the Orthopaedic Trauma Association Annual Meeting, Booth #805 or
online at hipfx.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2017 were
almost $4.8 billion. Smith &
Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on
Twitter or visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith & Nephew.
Certain marks registered US Patent and Trademark Office.
References:
1. American Academy of Orthopaedic Surgeons. Hip fractures in
seniors: a call for health system reform. Position Statement 1144.
Rosemont, IL: 1999.
2. Mundi S et al. Similar mortality rates in hip fracture
patients over the past 31 years: A systematic review of RCTs. Acta
Orthopaedica 2014; 85(1): 54-59.
3. Bentler SE, Liu L, Obrizan M, Cook EA, Wright KB, Geweke
JF, et al. The aftermath of hip fracture: discharge placement,
functional status change, and mortality. Am. J Epidemiol. 2009 Nov
15;170(10):1290-9. doi: 10.1093/aje/kwp266.
4. Nherera LM, Trueman P, Horner A, Johnstone AJ, Watson JT.
A meta-analysis of integrated compression screw compared to single
screw nails using a single lag screw or single helical blade screw
for intertrochanteric hip fractures. Rheumatol Orthop Med 2018;
3(4): 1-10. doi: 10.15761/ROM.1000156
5. Nherera LM, Trueman P, Horner A, Johnston AJ, Watson JT,
Fatoye FA. Comparing the costs and outcomes of an integrated twin
compression screw (ITCS) nail with standard of care using a single
lag screw or a single helical blade cephalomedullary nail in
patients with intertrochanteric hip fractures. Journal of
Orthopedic Surgery and Research (2018) 13:217. doi:
10.1186/s12018-018-0923-x
View original content to download
multimedia:http://www.prnewswire.com/news-releases/two-new-studies-demonstrate-intertan-intertrochanteric-antegrade-nail-improves-patient-outcomes-and-lowers-healthcare-costs-when-treating-hip-fractures-300731843.html
SOURCE Smith & Nephew